ArticleScientific reports2026
POTEF upregulation drives hepatocellular carcinoma progression via oncogenic signaling and immune modulation.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Members of the POTE gene family have been implicated in tumorigenesis across multiple malignancies. However, the biological and clinical significance of POTEF in hepatocellular carcinoma (HCC) remains unclear. Differential expression analyses of POTE family genes were performed using transcriptomic sequencing of 12 paired HCC and adjacent tissues and validated using TCGA and GEO datasets. POTEF expression was further confirmed by qRT-PCR, western blotting, and immunohistochemistry in clinical specimens. Functional assays, including CCK-8, wound-healing, apoptosis, and xenograft experiments, were conducted following POTEF overexpression or silencing in Huh7 cells. Transcriptomic analyses, pathway enrichment, and immune infiltration analyses were subsequently performed. POTEF was significantly upregulated in HCC tissues and was associated with unfavorable prognosis, advanced pathological stage, vascular invasion, and elevated serum AFP levels. Functional assays demonstrated that POTEF promoted hepatocellular carcinoma cell proliferation and migration while suppressing apoptosis in vitro, and xenograft experiments further showed that POTEF enhanced tumor growth in vivo.Transcriptomic profiling revealed enrichment of pathways related to extracellular matrix remodeling and carcinogenesis-associated signaling. Further experimental analyses suggested that POTEF may contribute to HCC progression partly through epithelial-mesenchymal transition-associated regulation. In addition, POTEF expression was positively associated with macrophage infiltration, particularly CD163-positive macrophage enrichment. Collectively, these findings indicate that POTEF is significantly upregulated in hepatocellular carcinoma and is associated with EMT-related regulation and macrophage infiltration, highlighting its potential clinical relevance as a diagnostic and prognostic biomarker.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.